Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 97

1.

Correction to: Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG).

Jaeckle KA, Anderson SK, Twohy EL, Dixon JG, Giannini C, Jenkins R, Egorin MJ, Sarkaria JN, Brown PD, Flynn PJ, Schwerkoske J, Buckner JC, Galanis E.

J Neurooncol. 2019 Jul;143(3):583. doi: 10.1007/s11060-019-03201-3.

2.

Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG).

Jaeckle KA, Anderson SK, Twohy EL, Dixon JG, Giannini C, Jenkins R, Egorin MJ, Sarkaria JN, Brown PD, Flynn PJ, Schwerkoske J, Buckner JC, Galanis E.

J Neurooncol. 2019 Jul;143(3):573-581. doi: 10.1007/s11060-019-03194-z. Epub 2019 May 22. Erratum in: J Neurooncol. 2019 Jun 5;:.

PMID:
31119479
3.

Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma.

Tun HW, Johnston PB, DeAngelis LM, Atherton PJ, Pederson LD, Koenig PA, Reeder CB, Omuro AMP, Schiff D, O'Neill B, Pulido J, Jaeckle KA, Grommes C, Witzig TE.

Blood. 2018 Nov 22;132(21):2240-2248. doi: 10.1182/blood-2018-02-835496. Epub 2018 Sep 27.

4.

Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572.

Schiff D, Jaeckle KA, Anderson SK, Galanis E, Giannini C, Buckner JC, Stella P, Flynn PJ, Erickson BJ, Schwerkoske JF, Kaluza V, Twohy E, Dancey J, Wright J, Sarkaria JN.

Cancer. 2018 Apr 1;124(7):1455-1463. doi: 10.1002/cncr.31219. Epub 2018 Jan 3.

5.

Treatment of a glioblastoma multiforme dural metastasis with stereotactic radiosurgery: A case report and select review of the literature.

Hintenlang LL, Miller DH, Kaleem T, Patel N, May BC, Tzou KS, Vallow LA, Buskirk SJ, Miller RC, Ko SJ, Jaeckle KA, Trifiletti DM, Peterson JL.

J Clin Neurosci. 2018 Feb;48:118-121. doi: 10.1016/j.jocn.2017.11.003. Epub 2017 Nov 26.

PMID:
29183682
6.

Leptomeningeal metastases: a RANO proposal for response criteria.

Chamberlain M, Junck L, Brandsma D, Soffietti R, Rudà R, Raizer J, Boogerd W, Taillibert S, Groves MD, Le Rhun E, Walker J, van den Bent M, Wen PY, Jaeckle KA.

Neuro Oncol. 2017 Apr 1;19(4):484-492. doi: 10.1093/neuonc/now183. Review.

7.

Quantification of the impact of enzyme-inducing antiepileptic drugs on irinotecan pharmacokinetics and SN-38 exposure.

Berg AK, Buckner JC, Galanis E, Jaeckle KA, Ames MM, Reid JM.

J Clin Pharmacol. 2015 Nov;55(11):1303-12. doi: 10.1002/jcph.543. Epub 2015 Jun 26.

8.

A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K.

Ma DJ, Galanis E, Anderson SK, Schiff D, Kaufmann TJ, Peller PJ, Giannini C, Brown PD, Uhm JH, McGraw S, Jaeckle KA, Flynn PJ, Ligon KL, Buckner JC, Sarkaria JN.

Neuro Oncol. 2015 Sep;17(9):1261-9. doi: 10.1093/neuonc/nou328. Epub 2014 Dec 18.

9.

Oligodendroglial tumors.

Jaeckle KA.

Semin Oncol. 2014 Aug;41(4):468-477. doi: 10.1053/j.seminoncol.2014.06.009. Epub 2014 Jun 30. Review.

PMID:
25173140
10.

Leptomeningeal metastasis: a Response Assessment in Neuro-Oncology critical review of endpoints and response criteria of published randomized clinical trials.

Chamberlain M, Soffietti R, Raizer J, Rudà R, Brandsma D, Boogerd W, Taillibert S, Groves MD, Le Rhun E, Junck L, van den Bent M, Wen PY, Jaeckle KA.

Neuro Oncol. 2014 Sep;16(9):1176-85. doi: 10.1093/neuonc/nou089. Epub 2014 May 27. Review.

11.

A randomized trial of bevacizumab for newly diagnosed glioblastoma.

Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ Jr, Mehta MP.

N Engl J Med. 2014 Feb 20;370(8):699-708. doi: 10.1056/NEJMoa1308573.

12.

Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.

Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal DT, Mahajan A, Schultz CJ, Erridge S, Baumert B, Hopkins KI, Tzuk-Shina T, Brown PD, Chakravarti A, Curran WJ Jr, Mehta MP.

J Clin Oncol. 2013 Nov 10;31(32):4085-91. doi: 10.1200/JCO.2013.49.6968. Epub 2013 Oct 7.

13.

Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial.

Galanis E, Anderson SK, Lafky JM, Uhm JH, Giannini C, Kumar SK, Kimlinger TK, Northfelt DW, Flynn PJ, Jaeckle KA, Kaufmann TJ, Buckner JC.

Clin Cancer Res. 2013 Sep 1;19(17):4816-23. doi: 10.1158/1078-0432.CCR-13-0708. Epub 2013 Jul 5.

14.

Metastases involving spinal cord, roots, and plexus.

Jaeckle KA.

Continuum (Minneap Minn). 2011 Aug;17(4):855-71. doi: 10.1212/01.CON.0000403799.87740.85.

PMID:
22810935
15.

Primary central nervous system B cell lymphoma with features intermediate between diffuse large B cell lymphoma and Burkitt lymphoma.

Jiang L, Li Z, Finn LE, Personnet DA, Edenfield B, Foran JM, Jaeckle KA, Reimer R, Menke DM, Ketterling RP, Tun HW.

Int J Clin Exp Pathol. 2012;5(1):72-6. Epub 2012 Jan 1.

16.

Transformation of low grade glioma and correlation with outcome: an NCCTG database analysis.

Jaeckle KA, Decker PA, Ballman KV, Flynn PJ, Giannini C, Scheithauer BW, Jenkins RB, Buckner JC.

J Neurooncol. 2011 Aug;104(1):253-9. doi: 10.1007/s11060-010-0476-2. Epub 2010 Dec 12.

17.

Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks.

Sarkaria JN, Galanis E, Wu W, Dietz AB, Kaufmann TJ, Gustafson MP, Brown PD, Uhm JH, Rao RD, Doyle L, Giannini C, Jaeckle KA, Buckner JC.

Clin Cancer Res. 2010 Nov 15;16(22):5573-80. doi: 10.1158/1078-0432.CCR-10-1453. Epub 2010 Oct 4.

18.

North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme.

Sarkaria JN, Galanis E, Wu W, Peller PJ, Giannini C, Brown PD, Uhm JH, McGraw S, Jaeckle KA, Buckner JC.

Int J Radiat Oncol Biol Phys. 2011 Oct 1;81(2):468-75. doi: 10.1016/j.ijrobp.2010.05.064. Epub 2010 Sep 23.

19.

Neurologic manifestations of neoplastic and radiation-induced plexopathies.

Jaeckle KA.

Semin Neurol. 2010 Jul;30(3):254-62. doi: 10.1055/s-0030-1255219. Epub 2010 Jun 24.

PMID:
20577932
20.

Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074.

Uhm JH, Ballman KV, Wu W, Giannini C, Krauss JC, Buckner JC, James CD, Scheithauer BW, Behrens RJ, Flynn PJ, Schaefer PL, Dakhill SR, Jaeckle KA.

Int J Radiat Oncol Biol Phys. 2011 Jun 1;80(2):347-53. doi: 10.1016/j.ijrobp.2010.01.070. Epub 2010 May 25.

21.

Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma.

Wu W, Lamborn KR, Buckner JC, Novotny PJ, Chang SM, O'Fallon JR, Jaeckle KA, Prados MD.

Neuro Oncol. 2010 Feb;12(2):164-72. doi: 10.1093/neuonc/nop019. Epub 2009 Dec 21.

22.

Phase II NCCTG trial of RT + irinotecan and adjuvant BCNU plus irinotecan for newly diagnosed GBM.

Jaeckle KA, Ballman KV, Giannini C, Schomberg PJ, Ames MM, Reid JM, McGovern RM, Safgren SL, Galanis E, Uhm JH, Brown PD, Hammack JE, Arusell R, Nikcevich DA, Morton RF, Wender DB, Buckner JC.

J Neurooncol. 2010 Aug;99(1):73-80. doi: 10.1007/s11060-009-0103-2. Epub 2010 Jan 9.

23.

Correlation of enzyme-inducing anticonvulsant use with outcome of patients with glioblastoma.

Jaeckle KA, Ballman K, Furth A, Buckner JC.

Neurology. 2009 Oct 13;73(15):1207-13. doi: 10.1212/WNL.0b013e3181bbfeca.

24.

Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study.

Galanis E, Jaeckle KA, Maurer MJ, Reid JM, Ames MM, Hardwick JS, Reilly JF, Loboda A, Nebozhyn M, Fantin VR, Richon VM, Scheithauer B, Giannini C, Flynn PJ, Moore DF Jr, Zwiebel J, Buckner JC.

J Clin Oncol. 2009 Apr 20;27(12):2052-8. doi: 10.1200/JCO.2008.19.0694. Epub 2009 Mar 23. Erratum in: J Clin Oncol. 2009 Jul 1;27(19):3262-3.

25.

Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results.

Santisteban M, Buckner JC, Reid JM, Wu W, Scheithauer BW, Ames MM, Felten SJ, Nikcevich DA, Wiesenfeld M, Jaeckle KA, Galanis E; North Central Cancer Treatment Group.

J Neurooncol. 2009 Apr;92(2):165-75. doi: 10.1007/s11060-008-9749-4. Epub 2008 Dec 10.

26.

Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.

Brown PD, Krishnan S, Sarkaria JN, Wu W, Jaeckle KA, Uhm JH, Geoffroy FJ, Arusell R, Kitange G, Jenkins RB, Kugler JW, Morton RF, Rowland KM Jr, Mischel P, Yong WH, Scheithauer BW, Schiff D, Giannini C, Buckner JC; North Central Cancer Treatment Group Study N0177.

J Clin Oncol. 2008 Dec 1;26(34):5603-9. doi: 10.1200/JCO.2008.18.0612. Epub 2008 Oct 27.

27.

North Central Cancer Treatment Group--achievements and perspectives.

Grothey A, Adjei AA, Alberts SR, Perez EA, Jaeckle KA, Loprinzi CL, Sargent DJ, Sloan JA, Buckner JC; North Central Cancer Treatment Group.

Semin Oncol. 2008 Oct;35(5):530-44. doi: 10.1053/j.seminoncol.2008.07.006. Review.

28.

Pathway analysis of primary central nervous system lymphoma.

Tun HW, Personett D, Baskerville KA, Menke DM, Jaeckle KA, Kreinest P, Edenfield B, Zubair AC, O'Neill BP, Lai WR, Park PJ, McKinney M.

Blood. 2008 Mar 15;111(6):3200-10. doi: 10.1182/blood-2007-10-119099. Epub 2008 Jan 9.

29.

Is there an association between meningioma and hormone replacement therapy?

Blitshteyn S, Crook JE, Jaeckle KA.

J Clin Oncol. 2008 Jan 10;26(2):279-82. doi: 10.1200/JCO.2007.14.2133.

PMID:
18182668
30.

Status epilepticus in patients with CNS metastases.

Blitshteyn S, Jaeckle KA.

Arch Neurol. 2007 Jun;64(6):916; author reply 916-7. No abstract available.

PMID:
17562948
31.

Detrimental effects of tumor progression on cognitive function of patients with high-grade glioma.

Brown PD, Jensen AW, Felten SJ, Ballman KV, Schaefer PL, Jaeckle KA, Cerhan JH, Buckner JC.

J Clin Oncol. 2006 Dec 1;24(34):5427-33.

PMID:
17135644
32.

The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme.

Ballman KV, Buckner JC, Brown PD, Giannini C, Flynn PJ, LaPlant BR, Jaeckle KA.

Neuro Oncol. 2007 Jan;9(1):29-38. Epub 2006 Nov 15.

33.

Neoplastic meningitis from systemic malignancies: diagnosis, prognosis and treatment.

Jaeckle KA.

Semin Oncol. 2006 Jun;33(3):312-23. Review.

PMID:
16769420
34.

Removal of an orbital metallic foreign body to facilitate magnetic resonance imaging: technical case report.

Deen HG, Miller DA, Kostick DA, Jaeckle KA.

Neurosurgery. 2006 May;58(5):E999; discussion E999.

PMID:
16639311
35.

Nonconvulsive status epilepticus in metastatic CNS disease.

Blitshteyn S, Jaeckle KA.

Neurology. 2006 Apr 25;66(8):1261-3.

PMID:
16636249
36.

Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177.

Krishnan S, Brown PD, Ballman KV, Fiveash JB, Uhm JH, Giannini C, Jaeckle KA, Geoffroy FJ, Nabors LB, Buckner JC; North Central Cancer Treatment Group.

Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):1192-9. Epub 2006 Apr 19.

PMID:
16626884
37.

Current strategies in treatment of oligodendroglioma: evolution of molecular signatures of response.

Jaeckle KA, Ballman KV, Rao RD, Jenkins RB, Buckner JC.

J Clin Oncol. 2006 Mar 10;24(8):1246-52. Review.

PMID:
16525179
38.

Ototoxicity of cisplatin plus standard radiation therapy vs. accelerated radiation therapy in glioblastoma patients.

Marshall NE, Ballman KV, Michalak JC, Schomberg PJ, Burton GV, Sandler HM, Cascino TL, Jaeckle KA, Buckner JC.

J Neurooncol. 2006 May;77(3):315-20.

PMID:
16273313
39.
40.

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.

Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K, Boni J, Peralba JM, Jenkins RB, Dakhil SR, Morton RF, Jaeckle KA, Scheithauer BW, Dancey J, Hidalgo M, Walsh DJ; North Central Cancer Treatment Group.

J Clin Oncol. 2005 Aug 10;23(23):5294-304. Epub 2005 Jul 5.

PMID:
15998902
41.

Neurological manifestations of neoplastic and radiation-induced plexopathies.

Jaeckle KA.

Semin Neurol. 2004 Dec;24(4):385-93. Review.

PMID:
15637650
42.

Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial.

Chang SM, Prados MD, Yung WK, Fine H, Junck L, Greenberg H, Robins HI, Mehta M, Fink KL, Jaeckle KA, Kuhn J, Hess K, Schold C.

Cancer. 2004 Apr 15;100(8):1712-6.

43.

Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.

Prados MD, Yung WK, Jaeckle KA, Robins HI, Mehta MP, Fine HA, Wen PY, Cloughesy TF, Chang SM, Nicholas MK, Schiff D, Greenberg HS, Junck L, Fink KL, Hess KR, Kuhn J; North American Brain Tumor Consortium study.

Neuro Oncol. 2004 Jan;6(1):44-54.

44.

Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study.

Prados MD, Yung WK, Fine HA, Greenberg HS, Junck L, Chang SM, Nicholas MK, Robins HI, Mehta MP, Fink KL, Jaeckle KA, Kuhn J, Hess KR, Schold SC Jr; North American Brain Tumor Consortium study.

Neuro Oncol. 2004 Jan;6(1):33-7.

45.

Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and survival.

Puduvalli VK, Hashmi M, McAllister LD, Levin VA, Hess KR, Prados M, Jaeckle KA, Yung WK, Buys SS, Bruner JM, Townsend JJ, Davis R, Sawaya R, Kyritsis AP.

Oncology. 2003;65(3):259-66.

PMID:
14657600
46.

Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study.

Jaeckle KA, Hess KR, Yung WK, Greenberg H, Fine H, Schiff D, Pollack IF, Kuhn J, Fink K, Mehta M, Cloughesy T, Nicholas MK, Chang S, Prados M; North American Brain Tumor Consortium.

J Clin Oncol. 2003 Jun 15;21(12):2305-11.

PMID:
12805331
47.
48.

Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas.

Levin VA, Hess KR, Choucair A, Flynn PJ, Jaeckle KA, Kyritsis AP, Yung WK, Prados MD, Bruner JM, Ictech S, Gleason MJ, Kim HW.

Clin Cancer Res. 2003 Mar;9(3):981-90.

49.

An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis.

Jaeckle KA, Batchelor T, O'Day SJ, Phuphanich S, New P, Lesser G, Cohn A, Gilbert M, Aiken R, Heros D, Rogers L, Wong E, Fulton D, Gutheil JC, Baidas S, Kennedy JM, Mason W, Moots P, Russell C, Swinnen LJ, Howell SB.

J Neurooncol. 2002 May;57(3):231-9.

PMID:
12125986
50.

Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme.

Groves MD, Puduvalli VK, Hess KR, Jaeckle KA, Peterson P, Yung WK, Levin VA.

J Clin Oncol. 2002 Mar 1;20(5):1383-8.

PMID:
11870183

Supplemental Content

Loading ...
Support Center